08 August 2021: Clinical Research
Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China
Zhihong Dai ABCDEF* , Yangyang Liu ABCDE* , Zhao Huangfu DF , Liang Wang CDEG* , Zhiyu Liu CDEG*DOI: 10.12659/MSM.930234
Med Sci Monit 2021; 27:e930234
Figure 1 Diagnostic performance of systematic biopsy (SB), targeted biopsy (TB), and a combined approach in our patient cohort. The overall positive rate for TB was higher than that of SB (45.87% vs 43.12%, P=0.156), leading to a higher diagnostic rate for clinically significant prostate cancer (csPCa) (28.90% vs 22.94%; P=0.034). Compared with SB+TB, SB misdiagnosed csPCa in 11.47% of cases while TB misdiagnosed csPCa in 5.50% of cases. GS – Gleason score.